Massachusetts Financial Services Co. MA Has $10.77 Million Position in Sanofi (NASDAQ:SNY)

Massachusetts Financial Services Co. MA lifted its position in Sanofi (NASDAQ:SNY - Free Report) by 25.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 194,122 shares of the company's stock after acquiring an additional 39,044 shares during the period. Massachusetts Financial Services Co. MA's holdings in Sanofi were worth $10,766,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD lifted its stake in Sanofi by 88.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company's stock worth $522,991,000 after purchasing an additional 5,091,304 shares in the last quarter. Point72 Asset Management L.P. increased its holdings in Sanofi by 969.6% in the 4th quarter. Point72 Asset Management L.P. now owns 950,649 shares of the company's stock valued at $45,850,000 after purchasing an additional 861,770 shares during the last quarter. Regal Partners Ltd purchased a new stake in shares of Sanofi during the fourth quarter worth $35,034,000. Vestal Point Capital LP increased its position in shares of Sanofi by 400.0% during the fourth quarter. Vestal Point Capital LP now owns 750,000 shares of the company's stock worth $36,172,000 after acquiring an additional 600,000 shares during the period. Finally, Northern Trust Corp increased its position in shares of Sanofi by 44.9% during the fourth quarter. Northern Trust Corp now owns 1,930,560 shares of the company's stock worth $93,111,000 after acquiring an additional 597,959 shares during the period. 14.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Stock Up 2.9%

Shares of Sanofi stock traded up $1.41 during trading hours on Wednesday, hitting $50.16. 2,231,264 shares of the company's stock traded hands, compared to its average volume of 2,313,811. The stock has a 50 day simple moving average of $49.58 and a 200-day simple moving average of $52.10. The company has a quick ratio of 0.69, a current ratio of 1.37 and a debt-to-equity ratio of 0.16. The company has a market cap of $123.02 billion, a PE ratio of 17.91, a PEG ratio of 1.11 and a beta of 0.48. Sanofi has a twelve month low of $45.80 and a twelve month high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. The business had revenue of $10.41 billion during the quarter, compared to the consensus estimate of $9.79 billion. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The company's revenue for the quarter was down 11.0% compared to the same quarter last year. During the same period last year, the firm earned $1.78 earnings per share. Equities research analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

SNY has been the subject of a number of research reports. BNP Paribas began coverage on shares of Sanofi in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price target for the company. Hsbc Global Res upgraded shares of Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. Guggenheim restated a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Morgan Stanley set a $56.00 price objective on shares of Sanofi in a research note on Monday, June 2nd. Finally, Barclays restated an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. Three equities research analysts have rated the stock with a hold rating, four have given a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat, Sanofi currently has an average rating of "Buy" and a consensus target price of $61.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.